Comparison of Seer Treatment Data With Medicare Claims
Bibliographic Data
| ID | 9103965 |
|---|---|
| Authors | Anne-Michelle Noone (National Cancer Institute), Anne‐Michelle Noone (0000-0001-6997-4004, National Cancer Institute, corresponding author), Jennifer L Lund (0000-0002-1108-0689, University of North Carolina at Chapel Hill), Ângela Mariotto (National Cancer Institute), Angela B Mariotto (0000-0003-2423-1834, National Cancer Institute, corresponding author), Kathleen Cronin (National Cancer Institute), Kathleen A Cronin (0000-0002-7282-9323, National Cancer Institute, corresponding author), Timothy S Mcneel (0000-0002-7141-5647, Information Management Services), Timothy McNeel (Information Management Services Inc., Calverton, MD), Dennis Deapen (0000-0002-0037-0277, University of Southern California), Joan L Warren (0000-0002-6467-6769, National Cancer Institute) |
| Year | 2016 |
| Volume | 54 |
| Issue | 9 |
| Pages | e55-e64 |
| Publication date | 2016-09-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Medical Care (JOURNAL) |
| Journal identifiers | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Publisher | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/mlr.0000000000000073 |
| PMID | 24638121 |
| OpenAlex | W2044619726 |
| Language | EN |
| Citations received | 10 |
| References cited | 21 |
BACKGROUND: The population-based Surveillance, Epidemiology, and End Results (SEER) registries collect information on first-course treatment, including surgery, chemotherapy, radiation therapy, and hormone therapy. However, the SEER program does not release data on chemotherapy or hormone therapy due to uncertainties regarding data completeness. Activities are ongoing to investigate the opportunity to supplement SEER treatment data with other data sources. METHODS: Using the linked SEER-Medicare data, we examined the validity of the SEER data to identify receipt of chemotherapy and radiation therapy among those aged 65 and older diagnosed from 2000 to 2006 with bladder, female breast, colorectal, lung, ovarian, pancreas, or prostate cancer and hormone therapy among men diagnosed with prostate cancer at age 65 or older. Treatment collected by SEER was compared with treatment as determined by Medicare claims, using Medicare claims as the gold standard. The κ, sensitivity, specificity, positive predictive values, and negative predictive values were calculated for the receipt of each treatment modality. RESULTS: The overall sensitivity of SEER data to identify chemotherapy, radiation, and hormone therapy receipt was moderate (68%, 80%, and 69%, respectively) and varied by cancer site, stage, and patient characteristics. The overall positive predictive value was high (>85%) for all treatment types and cancer sites except chemotherapy for prostate cancer. CONCLUSIONS: SEER data should not generally be used for comparisons of treated and untreated individuals or to estimate the proportion of treated individuals in the population. Augmenting SEER data with other data sources will provide the most accurate treatment information
Breast cancer · Cancer · Cancer registry · Chemotherapy · Gynecology · Hormone therapy · Population · Prostate cancer · Radiation therapy · Surveillance, Epidemiology, and End Results · Epidemiology · Frailty in Older Adults · Global Cancer Incidence and Screening · Health Systems, Economic Evaluations, Quality of Life · Internal Medicine · Medicine · Oncology
Variation in Colorectal Cancer Screening Practices According to Cardiovascular Disease Status and Race/Ethnicity
Utility of linking survey and registry data to evaluate interventions and policies to address disparities in breast cancer survivorship among young women
Racial disparities in the receipt of therapies for cancer, hypertension, and diabetes, and in mortality in a large population-based cohort of older men with prostate cancer
Risks of adverse health outcomes among older rural prostate cancer survivors in the Seer‐Medicare data
Socioeconomic and Racial Disparities in Cancer Stage at Diagnosis, Tumor Size, and Clinical Outcomes in a Large Cohort of Women with Breast Cancer, 2007–2016
Building Data Infrastructure for Disease-Focused Health Economics Research
Evaluation of the Completeness of Managed Care Data to Identify Cancer Diagnoses and Treatments for Patients in the Seer-Medicare Data
Compliance With Recommendations of the Surveillance, Epidemiology, and End Results (Seer) Treatment Data Use Agreement
The Association Between Socioeconomic Factors at Diagnosis and Survival in Medulloblastoma
Racial or Ethnic Disparities in Incidence, Treatment, and Prognosis of Adult Intracranial Meningiomas
External Validation of Medicare Claims for Breast Cancer Chemotherapy Compared With Medical Chart Reviews
Accuracy and Complexities of Using Automated Clinical Data for Capturing Chemotherapy Administrations
Utility of the Seer-Medicare Data to Identify Chemotherapy Use
Studying Radiation Therapy Using Seer-Medicare-Linked Data
Construct Validity of Medicare Chemotherapy Claims
Potential for Cancer Related Health Services Research Using a Linked Medicare-Tumor Registry Database
Identifying Specific Chemotherapeutic Agents in Medicare Data
Agreement of Medicare Claims and Tumor Registry Data for Assessment of Cancer-Related Treatment
Validation of Electronic Data on Chemotherapy and Hormone Therapy Use in HMOs
| Unique citing works | 10 |
|---|---|
| Citations per year | 2 |
| Citation span | 2021 - 2025 (5) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 9 |